Promising response of anaplastic lymphoma kinase-positive large B-cell lymphoma to crizotinib salvage treatment: Case report and review of literature

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 5, 2015, Pages 6977-6985

  Li, Jian ^a   Ouyang, Jian ^a   Zhou, Rongfu ^a   Chen, Bing ^a   Xu, Yong ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Anaplastic lymphoma kinase; Crizotinib; Non hodgkin lymphoma; Spleen

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; DEXAMETHASONE; GEMCITABINE; LACTATE DEHYDROGENASE; OXALIPLATIN;

ADULT; ARTICLE; BACKACHE; CASE REPORT; CERVICAL LYMPHADENOPATHY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DEATH; DRUG RESPONSE; FEVER; HUMAN; LARGE CELL LYMPHOMA; MALE; SALVAGE THERAPY; YOUNG ADULT;

EID: 84937046163     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. [1] Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th editon. swerdlow SH, editor. Lyon: IARC; 2008. pp. 253-254.
2. [2] Morgan EA, Nascimento AF. Anaplastic lymphoma kinase-positive large B-cell lymphoma: an underrecognized aggressive lymphoma. Adv Hematol 2012; 2012: 529572.
3. [3] Beltran B, Castillo J, Salas R. ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. J Hematol Oncol 2009; 2: 11.
4. [4] Ishida M, Yoshida K. Anaplastic lymphoma kinase-positive large B-cell lymphoma: a case report with emphasis on the cytological features of the pleural effusion. Int J Clin Exp Pathol 2013; 6: 2631-5.
5. [5] Choung HS, Kim HJ, Kim WS. Cytomorphology and molecular characterization of CLTC-ALK rearrangement in 2 cases of ALK-positive diffuse large B-cell lymphoma with extensive bone marrow involvement. Korean J Lab Med 2008; 28: 89-94.
6. [6] Delsol G, Lamant L, Mariamr B. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. Blood 1997; 89: 1483-90.
7. [7] Nath S, Mukherjee P. MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med 2014; 20: 332-42.
8. [8] Stachurski D, Miron PM, Al-Homsi S. Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma with a complex karyotype and cryptic 3’ ALK gene insertion to chromosome 4q22-24. Hum Pathol 2007; 38: 940-45.
9. [9] Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 1994; 263: 1281-4.
10. [10] Gascoyne RD, Lamant L, Martin-Subero JI. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases. Blood 2003; 102: 2568-73.
11. [11] Swerdlow SH, Campo E, Harris NL. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011; 117: 5019-32.
12. [12] Onciu M, Behm FG, Downing JR. ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases. Blood 2003; 102: 2642-4.
13. [13] Lee SE, Kang SY, Takeuchi K. Identification of RANBP2-ALK fusion in ALK positive diffuse large B-cell lymphoma. Hematol Oncol 2014; 32: 221-4.
14. [14] Takeuchi K, Soda M, Togashi Y. Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma. Haematologica 2011; 96: 464-7.
15. [15] Bedwell C, Rowe D, Moulton D. Cytogenetically complex SEC31A-ALK fusions are recurrent in ALK-positive large B-cell lymphomas. Hae-matologica 2011; 96: 343-6.
16. [16] Van Roosbroeck K, Cools J, Dierick D, Thomas J. ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions. Haematologica 2010; 95: 509-11.
17. [17] Zanelli M, Valli R, Capodanno I. Lymphoma Kinase-Positive Large B-Cell Lymphoma. Description of a case with an unexpected clinical outcome. Int J Surg Pathol 2014; 23:78-83.
18. [18] d’Amore ES, Visco C, Menin A. STAT3 pathway is activated in ALK-positive large B-cell lymphoma carrying SQSTM1-ALK rearrangement and provides a possible therapeutic target. Am J Surg Pathol 2013; 37: 780-6.
19. [19] Butrynski JE, D’Adamo DR, Hornick JL. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 2010; 363: 1727-33.
20. [20] Kwak EL, Bang YJ, Camidge DR. Anaplastic lymphoma Kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-703.
21. [21] Cerchietti L, Damm-Welk C, Vater I. Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas. PLoS One 2011; 6: e18436.
22. [22] Armstrong F, Duplantier MM, Trempat P, Hieblot C, Lamant L, Espinos E, Racaud-Sultan C, Allouche M, Campo E, Delsol G, Touriol C. Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells. Oncogene 2004; 23: 6071-82.
23. [23] Heuckmann JM, Balke-Want H, Malchers F, Peifer M, Sos ML, Koker M, Meder L, Lovly CM, Heukamp LC, Pao W, Küppers R, Thomas RK. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin Cancer Res 2012; 18: 4682-90.
24. [24] Wass M, Behlendorf T, Schädlich B. Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term response. Eur Haematol 2014; 92: 268-70.